JP2012531897A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012531897A5 JP2012531897A5 JP2012517843A JP2012517843A JP2012531897A5 JP 2012531897 A5 JP2012531897 A5 JP 2012531897A5 JP 2012517843 A JP2012517843 A JP 2012517843A JP 2012517843 A JP2012517843 A JP 2012517843A JP 2012531897 A5 JP2012531897 A5 JP 2012531897A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- item
- domain
- substitution
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 148
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 148
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 148
- 210000004027 cell Anatomy 0.000 claims description 57
- 238000006467 substitution reaction Methods 0.000 claims description 53
- 150000001413 amino acids Chemical group 0.000 claims description 32
- 150000007523 nucleic acids Chemical class 0.000 claims description 27
- 108020004707 nucleic acids Proteins 0.000 claims description 22
- 102000039446 nucleic acids Human genes 0.000 claims description 22
- 229940024606 amino acid Drugs 0.000 claims description 13
- 239000013604 expression vector Substances 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
- 239000004474 valine Substances 0.000 claims description 5
- 102000018697 Membrane Proteins Human genes 0.000 claims description 4
- 108010052285 Membrane Proteins Proteins 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 2
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 claims description 2
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 70
- 230000001580 bacterial effect Effects 0.000 description 23
- 239000012528 membrane Substances 0.000 description 11
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 5
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 3
- 108010021470 Fc gamma receptor IIC Proteins 0.000 description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 3
- 102100029206 Low affinity immunoglobulin gamma Fc region receptor II-c Human genes 0.000 description 3
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 3
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22199909P | 2009-06-30 | 2009-06-30 | |
| US61/221,999 | 2009-06-30 | ||
| PCT/US2010/040304 WO2011008517A2 (en) | 2009-06-30 | 2010-06-29 | Immunoglobulin fc polypeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012531897A JP2012531897A (ja) | 2012-12-13 |
| JP2012531897A5 true JP2012531897A5 (enExample) | 2013-07-18 |
| JP5683581B2 JP5683581B2 (ja) | 2015-03-11 |
Family
ID=43381018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012517843A Expired - Fee Related JP5683581B2 (ja) | 2009-06-30 | 2010-06-29 | 免疫グロブリンＦｃポリペプチド |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8679493B2 (enExample) |
| EP (1) | EP2448972A4 (enExample) |
| JP (1) | JP5683581B2 (enExample) |
| CN (1) | CN102549016B (enExample) |
| AU (1) | AU2010273763B2 (enExample) |
| CA (1) | CA2766065C (enExample) |
| WO (1) | WO2011008517A2 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008453B2 (en) * | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| KR20120118002A (ko) | 2009-12-08 | 2012-10-25 | 애보트 게엠베하 운트 콤파니 카게 | 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체 |
| WO2012109133A1 (en) * | 2011-02-07 | 2012-08-16 | Research Development Foundation | Engineered immunoglobulin fc polypeptides |
| EP3604330A1 (en) | 2011-02-25 | 2020-02-05 | Chugai Seiyaku Kabushiki Kaisha | Fcgammariib-specific fc antibody |
| KR20140059168A (ko) | 2011-04-21 | 2014-05-15 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 시신경 척수염 치료용 조성물 및 치료 방법 |
| MX340498B (es) | 2011-06-30 | 2016-07-11 | Chugai Pharmaceutical Co Ltd | Polipeptido heterodimerizado. |
| EP2762493B1 (en) | 2011-09-30 | 2021-06-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| CN110680920A (zh) * | 2011-09-30 | 2020-01-14 | 中外制药株式会社 | 诱导针对靶抗原的免疫应答的抗原结合分子 |
| BR112014013081A2 (pt) | 2011-11-30 | 2020-10-20 | Chugai Seiyaku Kabushiki Kaisha | veículo contendo fármaco em célula para formação de um complexo imune |
| PE20190907A1 (es) | 2012-01-27 | 2019-06-26 | AbbVie Deutschland GmbH and Co KG | Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| KR102266819B1 (ko) | 2013-04-29 | 2021-06-18 | 에프. 호프만-라 로슈 아게 | Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법 |
| CN103524625B (zh) * | 2013-09-24 | 2015-03-18 | 众森源生物技术（江苏）有限公司 | 一种新型诱导抗体产生的方法 |
| RU2698969C2 (ru) | 2014-01-15 | 2019-09-02 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с улучшенной способностью связываться с белком а |
| BR112016016416A2 (pt) * | 2014-01-15 | 2017-10-03 | Hoffmann La Roche | VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS |
| US10780182B2 (en) * | 2014-04-25 | 2020-09-22 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
| CN106661125B (zh) | 2014-05-02 | 2021-10-01 | 动量制药公司 | 涉及工程化Fc构建体的组合物和方法 |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| SG10202007232WA (en) * | 2015-01-30 | 2020-09-29 | Momenta Pharmaceuticals Inc | Fcrn antibodies and methods of use thereof |
| SG11201706014PA (en) | 2015-02-05 | 2017-08-30 | Chugai Pharmaceutical Co Ltd | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| EP3256490A1 (en) * | 2015-02-09 | 2017-12-20 | Research Development Foundation | Engineered immunoglobulin fc polypeptides displaying improved complement activation |
| JP6665485B2 (ja) * | 2015-10-29 | 2020-03-13 | 東ソー株式会社 | 抗体依存性細胞傷害活性に基づく抗体の分析方法 |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| US12391759B2 (en) | 2016-03-02 | 2025-08-19 | Momenta Pharmaceuticals, Inc. | Methods related to engineered Fc constructs |
| WO2017180842A1 (en) | 2016-04-15 | 2017-10-19 | Bioatla, Llc | Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof |
| KR102635635B1 (ko) | 2016-05-23 | 2024-02-14 | 모멘타 파머슈티컬스 인코포레이티드 | 유전자 조작 Fc 작제물에 관한 조성물 및 방법 |
| CA3030099A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| CA3032415A1 (en) | 2016-07-29 | 2018-02-01 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
| KR102538749B1 (ko) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| CN110214148A (zh) | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | 含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白 |
| EP3526246A1 (en) * | 2016-10-17 | 2019-08-21 | Vetoquinol SA | Modified antibody constant region |
| CN110650748B (zh) | 2017-01-06 | 2024-01-02 | 动量制药公司 | 与经工程改造的Fc构建体相关的组合物和方法 |
| JP2020517242A (ja) | 2017-04-21 | 2020-06-18 | スターテン・バイオテクノロジー・ベー・フェー | 抗ＡｐｏＣ３抗体およびその使用方法 |
| AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| CN111032688A (zh) | 2017-08-11 | 2020-04-17 | 研究发展基金会 | 用于延长的血清半衰期的工程化抗体fc变体 |
| BR112020008514A2 (pt) | 2017-10-31 | 2020-10-20 | Staten Biotechnology B.V. | anticorpos anti-apoc3 e métodos de uso dos mesmos |
| US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
| EP4640703A2 (en) | 2017-11-14 | 2025-10-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-c1s antibodies and methods of use |
| AU2018383600B2 (en) | 2017-12-11 | 2025-10-02 | Abalone Bio, Inc. | Yeast display of proteins in the periplasmic space |
| AU2018386193B2 (en) | 2017-12-13 | 2025-04-24 | Momenta Pharmaceuticals, Inc. | FcRn antibodies and methods of use thereof |
| CN108676094B (zh) * | 2017-12-31 | 2021-07-20 | 武汉班科生物技术股份有限公司 | 人IgG抗体Fc段CH2结构域突变体及制备方法与应用 |
| JP7551499B2 (ja) * | 2018-03-21 | 2024-09-17 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｆｃバリアント組成物およびその使用方法 |
| CA3097625A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
| AU2019256539A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
| EP3781598A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| US20250346676A1 (en) * | 2018-07-11 | 2025-11-13 | Momenta Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CCR4 |
| EP3835321A4 (en) | 2018-08-10 | 2022-11-02 | Chugai Seiyaku Kabushiki Kaisha | ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF |
| US20210395716A1 (en) * | 2018-10-11 | 2021-12-23 | Valerion Therapeutics, Llc | Methods and compositions for treatment of protein aggregation-based disorders |
| CR20210239A (es) | 2018-10-12 | 2021-12-15 | Xencor Inc | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas |
| US11618776B2 (en) | 2018-12-20 | 2023-04-04 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains |
| SG11202110626SA (en) * | 2019-03-27 | 2021-10-28 | Umc Utrecht Holding Bv | Engineered iga antibodies and methods of use |
| BR112021021689A2 (pt) | 2019-05-15 | 2022-03-22 | Chugai Pharmaceutical Co Ltd | Molécula de ligação a antígeno, composição farmacêutica, e método |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| CN113121677B (zh) * | 2019-12-31 | 2023-06-27 | 周易 | 一种得到高纯度异源抗体的方法 |
| CN116635053A (zh) * | 2020-11-12 | 2023-08-22 | 生物蛋白有限公司 | 以抗axl抗体、抗体片段和其免疫结合物治疗表达axl的癌症的方法 |
| CN115466323B (zh) * | 2022-09-13 | 2025-07-01 | 宁波博睿瀚达生物科技有限公司 | 一种分离分泌性白细胞蛋白酶抑制因子的方法 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5576195A (en) * | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| AU600575B2 (en) * | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| WO1990005144A1 (en) * | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5578464A (en) * | 1989-10-31 | 1996-11-26 | Schering Corporation | E. coli secretory strains |
| US6172197B1 (en) * | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6916605B1 (en) * | 1990-07-10 | 2005-07-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5858657A (en) * | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5994514A (en) * | 1991-08-14 | 1999-11-30 | Genentech, Inc. | Immunoglobulin variants |
| ATE408012T1 (de) * | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5702892A (en) * | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
| US7264963B1 (en) * | 1995-08-18 | 2007-09-04 | Morphosys Ag | Protein(poly)peptide libraries |
| FR2739629B1 (fr) * | 1995-10-06 | 1997-12-26 | Systems Bio Ind | Utilisation d'un systeme de secretion sec-dependant pour secreter des proteines normalement secretees par un systeme de secretion sec-independant, bacteries les contenant et leur utilisation |
| DE19628805A1 (de) * | 1996-07-17 | 1998-01-22 | Basf Ag | Verfahren zur Herstellung von Caprolactam aus 6-Aminocapronitril |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| WO1999006587A2 (en) * | 1997-08-01 | 1999-02-11 | Morphosys Ag | Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex |
| US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US7183387B1 (en) * | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| BR0008758A (pt) * | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ATE418340T1 (de) * | 1999-05-06 | 2009-01-15 | Univ Wake Forest | Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen |
| EP1077263A1 (de) * | 1999-07-29 | 2001-02-21 | F.Hoffmann-La Roche Ag | Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen durch Co-Sekretion von Chaperonen |
| KR100615887B1 (ko) * | 2000-04-07 | 2006-08-25 | 삼성전자주식회사 | 되먹임 기능을 갖는 무선 통신 시스템 및 그 방법 |
| EP1354056B1 (en) * | 2000-10-10 | 2014-11-26 | Danisco US Inc. | Enhanced secretion of a polypeptide by a microorganism |
| US7094571B2 (en) * | 2000-10-27 | 2006-08-22 | The Board Of Regents Of The University Of Texas System | Combinatorial protein library screening by periplasmic expression |
| US6979556B2 (en) * | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
| ATE298794T1 (de) * | 2000-12-20 | 2005-07-15 | Altana Pharma Ag | Verfahren zur herstellung und reinigung von sekretierten proteinen und herstellung von protein-arrays |
| US7419783B2 (en) * | 2001-11-05 | 2008-09-02 | Research Development Foundation | Engineering of leader peptides for the secretion of recombinant proteins in bacteria |
| US20040002587A1 (en) * | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US7662925B2 (en) * | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US8188231B2 (en) * | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20030219870A1 (en) * | 2002-03-23 | 2003-11-27 | George Georgiou | Secretion of proteins with multiple disulfide bonds in bacteria and uses thereof |
| US7611866B2 (en) * | 2002-07-15 | 2009-11-03 | Board Of Regents, The University Of Texas System | Selection of bacterial inner-membrane anchor polypeptides |
| US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| CA2499816C (en) * | 2002-09-27 | 2013-07-30 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| EP1587540B1 (en) * | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| US7960512B2 (en) * | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US8084582B2 (en) * | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| WO2005077981A2 (en) * | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| EP2053062A1 (en) * | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
| US7229792B2 (en) * | 2004-05-03 | 2007-06-12 | Vinod Pandiripally | Method of producing recombinant proteins |
| AU2005335714B2 (en) * | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| BRPI0517837A (pt) * | 2004-11-12 | 2008-10-21 | Xencor Inc | variantes fc com ligação alterada a fcrn |
| RU2412200C2 (ru) * | 2004-11-12 | 2011-02-20 | Ксенкор, Инк. | Fc-ВАРИАНТЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ С FcRn |
| WO2006089231A2 (en) * | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
| GB0503927D0 (en) * | 2005-02-25 | 2005-04-06 | Nokia Corp | Location services in a communication system |
| PL1919503T3 (pl) * | 2005-08-10 | 2015-04-30 | Macrogenics Inc | Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania |
| EP2155789B1 (en) * | 2007-05-01 | 2013-07-24 | Research Development Foundation | Immunoglobulin fc libraries |
-
2010
- 2010-06-29 JP JP2012517843A patent/JP5683581B2/ja not_active Expired - Fee Related
- 2010-06-29 WO PCT/US2010/040304 patent/WO2011008517A2/en not_active Ceased
- 2010-06-29 CA CA2766065A patent/CA2766065C/en active Active
- 2010-06-29 EP EP10800284A patent/EP2448972A4/en not_active Withdrawn
- 2010-06-29 CN CN201080038758.4A patent/CN102549016B/zh not_active Expired - Fee Related
- 2010-06-29 AU AU2010273763A patent/AU2010273763B2/en not_active Ceased
- 2010-06-30 US US12/827,386 patent/US8679493B2/en active Active
-
2014
- 2014-02-14 US US14/181,594 patent/US20140235482A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012531897A5 (enExample) | ||
| CA2766065C (en) | Immunoglobulin fc polypeptides | |
| CA2826467C (en) | Engineered immunoglobulin fc polypeptides | |
| TW201202419A (en) | Antigen-binding molecules that promote antigen clearance | |
| CN116194486B (zh) | 异二聚体Fc多肽 | |
| KR20200143730A (ko) | 3가 삼중 특이성 항체 구조물 | |
| JP2021508246A (ja) | 新規抗原結合部分の特異性試験のためのｃａｒ−ｔ細胞アッセイ | |
| JP2024167352A (ja) | ｍＲＮＡディスプレイ抗体ライブラリー及び方法 | |
| JP2022501389A (ja) | 可溶性ｂｃｍａに対する抗体 | |
| KR101934578B1 (ko) | 소수성 테일 도메인이 제거된 먹장어 유래 VLRB 단백질에 마우스 항체 유래 Fc 도메인이 연결된 융합 단백질 및 이의 용도 | |
| CN114829407B (zh) | 利用哺乳动物展示筛选FcγR特异性结合Fc | |
| KR101972894B1 (ko) | 소수성 테일 도메인이 제거된 먹장어 유래 vlrb 단백질에 칠성장어 유래 vlrb 단백질의 c 말단 서열이 연결된 융합 단백질 및 이의 용도 | |
| TW202321312A (zh) | 包含基於ｍｈｃ或ｍｈｃ樣蛋白的異源二聚體的二價雙特異性嵌合抗體 | |
| CN112955240A (zh) | 抗体FcRn结合的修饰 | |
| JP2006282521A (ja) | ニワトリキメラ抗体およびその利用 | |
| HK40085483A (en) | Heterodimer fc polypeptide | |
| CN120752260A (zh) | 包含人类CD1b (分化簇1)蛋白的异二聚体的抗体样分子 |